Clinical Pharmacology & Therapeutics · 2003 · 23 citations · 36 references
MedicineBiochemistryPharmacologyDrug MetabolismGene ExpressionMetabolismCytochrome P450 EnzymesCytochrome P450-mediated MetabolismHepatic MetabolismHepatic PathophysiologyLiver DiseaseLiver PhysiologyCyp2d6 GenotypeCytochrome EnzymesCytochrome P450 2D6Cytochrome P450 Enzyme ActivityCytochrome P450 Expression RegulationCytochrome P450 Human Liver MicrosomesExtrahepatic Cytochrome P450 EnzymesHydroxylation
Cytochrome p450 (CYP) 2D6 activity exhibits wide intersubject variation even among individuals with similar genotypes in whom the active enzyme is expressed. There is, therefore, a need to understand the mechanisms involved in determining its activity. The relationship of messenger ribonucleic acid (mRNA) expression to CYP2D6 activity has been evaluated in hepatic and extrahepatic tissues to test the hypothesis of coordinated regulation. In human liver microsomes, there was a greater than 25-fold variation in both bufuralol hydroxylation and concentration of mRNA for CYP2D6, with a significant association between variables (n = 20; Spearman correlation coefficient [r(s)] = 0.85, P <.001). In normal subjects, there was a similar extent of interindividual variation in in vivo activity of CYP2D6, measured as the debrisoquin (INN, debrisoquine) recovery ratio, and in mRNA for CYP2D6 in peripheral blood mononuclear cells, with a significant association between variables (n = 78; r(s) = 0.56 [95% confidence interval, 0.35 to 0.73], P <.001), whereas no association was found between mRNA for CYP2D6 and CYP2E1 activity. Recipients of liver transplants, at a time of stable liver function, had a similar relationship between debrisoquin recovery ratio and concentration of mRNA for CYP2D6 in peripheral blood mononuclear cells (n = 27; r(s) = 0.74 [95% confidence interval, -0.16 to 0.44], P <.001). Three recipients, who had CYP2D6*4/*4 genotypes, remained phenotypically poor metabolizers for CYP2D6 after liver transplantation. Collectively, these results imply that transcriptional regulation of mRNA for CYP is a major determinant of in vivo activity and that regulation of intrahepatic and extrahepatic enzymes is coordinated, possibly through a mechanism that is predominantly extrahepatic.
36
Nomenclature for human CYP2D6 alleles
Ann K. Daly, Jürgen Brockmöller, Franck Broly et al. · Pharmacogenetics · 1996 · 400 citations
Identification of the primary gene defect at the cytochrome P450 CYP2D locus
Alan C. Gough, John S. Miles, Nigel K. Spurr et al. · Nature · 1990 · 306 citations